Fasting improves therapeutic response in hepatocellular carcinoma through 
p53-dependent metabolic synergism.

Krstic, Jelena; Reinisch, Isabel; Schindlmaier, Katharina; Galhuber, Markus; Riahi, Zina; Berger, Natascha; Kupper, Nadja; Moyschewitz, Elisabeth; Auer, Martina; Michenthaler, Helene; Nössing, Christoph; Depaoli, Maria R; Ramadani-Muja, Jeta; Usluer, Sinem; Stryeck, Sarah; Pichler, Martin; Rinner, Beate; Deutsch, Alexander J A; Reinisch, Andreas; Madl, Tobias; Chiozzi, Riccardo Zenezini; Heck, Albert J R; Huch, Meritxell; Malli, Roland; Prokesch, Andreas

doi:10.1126/sciadv.abh2635

Item

ITEM ACTIONSEXPORT

Add to Basket

Local TagsRelease HistoryDetailsSummary

Released

Journal Article

Fasting improves therapeutic response in hepatocellular carcinoma through p53-dependent metabolic synergism.

MPS-Authors

/cone/persons/resource/persons240648

Huch, Meritxell
Max Planck Institute for Molecular Cell Biology and Genetics, Max Planck Society;

External Resource

No external resources are shared

Fulltext (restricted access)

There are currently no full texts shared for your IP range.

Fulltext (public)

There are no public fulltexts stored in PuRe

Supplementary Material (public)

There is no public supplementary material available

Citation

Krstic, J., Reinisch, I., Schindlmaier, K., Galhuber, M., Riahi, Z., Berger, N., et al. (2022). Fasting improves therapeutic response in hepatocellular carcinoma through p53-dependent metabolic synergism. Science advances, 8(3): eabh2635. doi:10.1126/sciadv.abh2635.

Cite as: https://hdl.handle.net/21.11116/0000-000B-0347-2

Abstract

Cancer cells voraciously consume nutrients to support their growth, exposing metabolic vulnerabilities that can be therapeutically exploited. Here, we show in hepatocellular carcinoma (HCC) cells, xenografts, and patient-derived organoids that fasting improves sorafenib efficacy and acts synergistically to sensitize sorafenib-resistant HCC. Mechanistically, sorafenib acts noncanonically as an inhibitor of mitochondrial respiration, causing resistant cells to depend on glycolysis for survival. Fasting, through reduction in glucose and impeded AKT/mTOR signaling, prevents this Warburg shift. Regulating glucose transporter and proapoptotic protein expression, p53 is necessary and sufficient for the sorafenib-sensitizing effect of fasting. p53 is also crucial for fasting-mediated improvement of sorafenib efficacy in an orthotopic HCC mouse model. Together, our data suggest fasting and sorafenib as rational combination therapy for HCC with intact p53 signaling. As HCC therapy is currently severely limited by resistance, these results should instigate clinical studies aimed at improving therapy response in advanced-stage HCC.